Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR

Journal of Medicinal Chemistry

Volumn 54, Issue 24, 2011, Pages 8555-8562

  Viegas, Aldino ^a   Manso, João ^a   Corvo, Marta C ^a   Marques, M Manuel B ^a   Cabrita, Eurico J ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; HETERODIMER; IBUPROFEN; KETOROLAC; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; SATURATION TRANSFER DIFFERENCE NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANIMALS; BINDING, COMPETITIVE; CATALYTIC DOMAIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; FEMALE; IBUPROFEN; KETOROLAC; MAGNETIC RESONANCE SPECTROSCOPY; MALE; SHEEP;

EID: 84055217570     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201090k     Document Type: Article

References (31)

1. Vane, J. R; Botting, R M. Anti-inflammatory drugs and their mechanism of action. Inflammation Res. 1998, 47 (Suppl. 2), S78-S87.
2. Vane, J. R Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231, 232-235.
3. Vane, J. R Introduction: mechanism of action of NSAIDs. Br. J. Rheumatol. 1996, 35 (Suppl. 1), 1-3.
4. Xie, W. L.; Chipman, J. G.; Robertson, D. L.; Erikson, R L.; Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA. 1991, 88, 2692-2696.
5. Marnett, L. J.; Rowlinson, S. W.; Goodwin, D. C.; Kalgutkar, A. S.; Lanzo, C. A. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. 1999, 274, 22903-22906.
6. Kurumbail, R G.; Stevens, A M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384, 644-648.
7. Smith, W. L.; Garavito, R M.; DeWitt, D. L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 1996,271,33157-33160.
8. Grosser, T.; Fries, S.; FitzGerald, G A Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006, 116, 4-15.
9. Blobaum, A. L.; Marnett, L. J. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 2007, 50, 1425-1441.
10. Dannhardt, G.; Kiefer, W. Cyclooxygenase inhibitors-current status and future prospects. Eur. J. Med. Chem. 2001, 36, 109-126.
11. Chakraborti, A. K.; Garg, S. K.; Kumar, R; Motiwala, H. F.; Jadhavar, P. S. Progress in COX-2 inhibitors: a journey so far. Curr. Med. Chem. 2010, 17, 1563-1593.
12. Marnett, L. J. The COXIB experience: a look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 265-290.
13. Limongelli, V.; Bonomi, M.; Marinelli, L.; Gervasio, F. L.; Cavalli, A.; Novellino, E.; Parrinello, M. Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition. Proc. Natl. Acad. Sci. USA. 2010, 107, 5411-5416.
14. Rimon, G.; Sidhu, R S.; Lauver, D. A.; Lee, J. Y.; Sharma, N. P.; Yuan, C.; Frieler, R A.; Trievel, R C.; Lucchesi, B. R; Smith, W. L. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc. Natl. Acad. Sci. USA. 2010, 107, 28-33.
15. Dong, L.; Vecchio, A. J.; Sharma, N. P.; Jurban, B. J.; Malkowski, M. G.; Smith, W. L. Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J. Biol. Chem. 2011, 286, 19035-19046.
16. Sharma, N. P.; Dong, L.; Yuan, C.; Noon, K. R.; Smith, W. L. Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids. Mol. Pharmacol. 2010, 77, 979-986.
17. Kulmacz, R.; Lands, W. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J. Biol. Chem. 1985, 260, 12572-12578.
18. Meyer, B.; Peters, T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem., Int. Ed. 2003, 42, 864-890.
19. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem., Int. Ed. 1999, 38, 1784-1788.
20. Viegas, A.; Manso, J.; Nobrega, F. L.; Cabrita, E. J. Saturation-transfer difference (STD) NMR: a simple and fast method for ligand screening and characterization of protein binding. J. Chem. Educ. 2011, 88, 990-994.
21. Prusakiewicz, J. J.; Duggan, K. C.; Rouzer, C. A.; Marnett, L. J. Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry 2009, 48, 7353-7355.
22. Johnson, J. L.; Wimsatt, J.; Buckel, S. D.; Dyer, R. D.; Maddipati, K. R. Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. Arch. Biochem. Biophys. 1995, 324, 26-34.
23. Walker, M. C.; Kurumbail, R. G.; Kiefer, J. R.; Moreland, K. T.; Koboldt, C. M.; Isakson, P. C.; Seibert, K.; Gierse, J. K. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem. J. 2001, 357, 709-718.
24. Yuan, Y.; Wen, X.; Sanders, D. A.; Pinto, B. M. Exploring the mechanism of binding of UDP-galactopyranose to UDP-galactopyranose mutase by STD-NMR spectroscopy and molecular modeling. Biochemistry 2005, 44, 14080-14089.
25. Barnett, J.; Chow, J.; Ives, D.; Chiou, M.; Mackenzie, R.; Osen, E.; Nguyen, B.; Tsing, S.; Bach, C.; Freire, J.; Chan, H.; Sigal, E.; Ramesha, C. Purification, characterization and selective-inhibition of human prostaglandin-G/H synthase-1 and synthase-2 expressed in the baculovirus system. Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1994, 1209, 130-139.
26. Waterbury, L. D.; Silliman, D.; Jolas, T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr. Med. Res. Opin. 2006, 22, 1133-1140.
27. Laneuville, O.; Breuer, D. K.; Dewitt, D. L.; Hla, T.; Funk, C. D.; Smith, W. L. Differential inhibition of human prostaglandin endoperoxide-H synthase-1 and synthase-2 by nonsteroidal antiinflammatory drugs. J. Pharmacol. Exp. Ther. 1994, 271, 927-934.
28. Gierse, J. K.; Koboldt, C. M.; Walker, M. C.; Seibert, K.; Isakson, P. C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 1999, 339, 607-614.
29. Selinsky, B. S.; Gupta, K.; Sharkey, C. T.; Loll, P. J. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry 2001, 40, 5172-5180.
30. Rowlinson, S. W.; Kiefer, J. R.; Prusakiewicz, J. J.; Pawlitz, J. L.; Kozak, K. R.; Kalgutkar, A. S.; Stallings, W. C.; Kurumbail, R. G.; Marnett, L. J. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J. Biol. Chem. 2003, 278, 45763-45769.
31. Wang, Y. S.; Liu, D. J.; Wyss, D. F. Competition STD NMR for the detection of high-affinity ligands and NMR-based screening. Magn. Reson. Chem. 2004, 42, 485-489.